Mechanism of Action

Mechanism of Action

video_preview_play_button

Synergistic Ratio

Fixed 1:5 molar ratio of daunorubicin and cytarabine has been shown to produce a synergistic effect in vitro3

Prolonged Delivery

Synergistic molar ratio maintained for a prolonged period of time – over 24 hours after administration3,4

High Concentration*

Liposomes accumulate and persist in the bone marrow in high concentrations*3

Preferential Uptake*

Vyxeos Liposomal is preferentially taken up by leukaemia cells vs normal bone marrow cells*3

  *shown in animal models

References

  1. Tolcher AW, Mayer LD. Future Oncol 2018; 14(13): 1317-1332
  2. Lancet JE et alJ Clin Oncol 2018; 36(26): 2684-2692
  3. Vyxeos Liposomal – Summary of Product Characteristics, October 2019
  4. Tardi P et al. Leuk Res 2009; 33(1): 129-139

 

ADVERSE EVENTS REPORTING

 

Reporting of side effects: Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse reactions via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email: AEreporting@jazzpharma.com or by fax to +44 (0) 1865 598765

 

INT-VYX-1900008 | January 2020